Earnings Call
Apr 29, 2026
Q1 FY2026
EPS Estimate
3.05
EPS Actual
3.57
Post-Earnings Close
$194.38
Earnings Reaction
+6.0%
Biogen's first quarter 2026 results came in ahead of expectations on both the top and bottom lines, with total revenue of $2.5 billion (up 2% year-over-year) and non-GAAP diluted EPS of $3.57 (up 18% year-over-year), comfortably clearing the $2.96 consensus estimate. The headline numbers, however, are arguably secondary to the strategic narrative unfolding at the company: a business that spent four years in revenue decline is now generating meaningful growth from a diversified portfolio, and management is layering a pending transformative acquisition on top of that improving base.
Report generated on May 1, 2026
AI-generated earnings analysis. Not investment advice.
Chief Executive Officer
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
Read the full BIIB analysis
The complete report, with key themes, analyst Q&A summary, notable quotes, and market context — is free with an account. No password, no card.